Table 2.

Efficacy Endpoints^*

	End of Treatment (EOT)		End of Follow-up (EOF)
Endpoints	n=28 (%)	95% Confidence Intervals (%)	n=28 (%)	95% Confidence Intervals (%)
HBsAg loss	0 (0)	(0.0–12.3)	0 (0)	(0.0–12.3)
HBsAg seroconversion	0 (0)	(0.0–12.3)	0 (0)	(0.0–12.3)
HBeAg loss**	1 (4)	(0.1–18.3)	1 (4)	(0.1–18.3)
HBeAg seroconversion	1 (4)	(0.1–18.3)	1 (4)	(0.1–18.3)
HBV DNA< 20 IU/mL	5 (18)	(6.1–36.9)	0 (0)	(0.0–12.3)
HBV DNA≤ 1000 IU/mL	26 (93)	(76.5–99.1)	0 (0)	(0.0–12.3)
ALT< 1x ULN	11 (39)	(21.5–59.4)	13 (46)	(27.5–66.1)
ALT< 1.5 x ULN	16 (57)	(24.5–62.8)	21 (75)	(55.1–89.3)
Primary Endpoint:
HBeAg loss** & HBV DNA≤ 1000 IU/mL	1 (4)	(0.1–18.3)	0 (0)	(0.0–12.3)

^*Analyses were performed using all enrolled participants.

^**The individual with discrepant qualitative (positive) and quantitative (negative) HBeAg results over time was not regarded as HBeAg loss.